Postoperative Adjuvant Treatment Options in Resected Non–Small-Cell Lung Cancer

doi:10.21203/rs.3.rs-1334487/v1

PDF

Research Article

Postoperative Adjuvant Treatment Options in Resected Non–Small-Cell Lung Cancer

https://doi.org/10.21203/rs.3.rs-1334487/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted 15 Feb, 2022

You are reading this latest preprint version

Lung cancer remains the most common malignancies and the leading cause of mortality worldwide, more than 80% of which are Non–Small-Cell Lung Cancer (NSCLC). For approximately one-third of diagnosed NSCLCs with stage I–IIIA disease, surgical resection is recommended as a preferred curative treatment. Nevertheless, many resected NSCLC patients experience recurrence.

The adjuvant treatment option of patients with resected Non–Small-Cell Lung Cancer (NSCLC) remains unstandardized. At present, there are many postoperative adjuvant therapy options for resected NSCLC, including chemotherapy, targeted therapy, chemotherapy and immunotherapy. However, which adjuvant therapy is better for which patients is remaining to be explored.

With further development of ctDNA-based molecular residual disease (MRD) research, more accurate clinical trials may be needed in the future to refine more comparison of biomarker for more precise treatment in postoperative adjuvant therapy in the future.

In our manuscript, we discussed the status of possible markers and possible future clinical trials in combination with MRD. Finer patient stratification and adjuvant treatment options need to be further explored.

Non–Small-Cell Lung Cancer

surgical resection

adjuvant treatment

molecular residual disease

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication

Informed consent was obtained from the patient for participating in this case.

Availability of data and materials

Not applicable.

Competing interests

The authors declare that they have no Competing interests.

Funding

This study was supported by the Shandong Provincial Natural Science Foundation (grant number: ZR201911120168).

Authors' contributions

Qiuyu Hou and Ningning Luo collected data and wrote the first draft of the manuscript. Xinglong Fan supervised the work. All authors critically reviewed the manuscript.

Acknowledgements

The authors thank Chuang Qi, Tingting Sun, and Xiaofeng Zhu from Simceredx for the kindly assistance.

Compliance with Ethical Standards

Disclosure of potential conflicts of interest

The authors declare that they have no conflicts of interest.

Research involving Human Participants and/or Animals

No, this research did not involve human participants.

Informed consent

Not applicable.

Kris MG, Gaspar LE, Chaft JE, et al (2017) Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol 35(25):2960-2974. doi:10.1200/JCO.2017.72.4401
Yang XN, Yan HH, Wang J, et al (2021) Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. JTO Clin Res Rep 3(1):100257. doi:10.1016/j.jtocrr.2021.100257
Zhong WZ, Wang Q, Mao WM, et al (2018) Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 19(1):139-148. doi:10.1016/S1470-2045(17)30729-5
Yue D, Xu S, Wang Q, et al (2018) Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med 6(11):863-873. doi:10.1016/S2213-2600(18)30277-7
Kelly K, Altorki NK, Eberhardt WE, et al (2015) Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 33(34):4007-4014. doi:10.1200/JCO.2015.61.8918
Xu ST, Xi JJ, Zhong WZ, et al (2019) The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104). J Thorac Oncol 14(3):503-512. doi:10.1016/j.jtho.2018.11.020
Zhong WZ, Wang Q, Mao WM, et al (2021) Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol 39(7):713-722. doi:10.1200/JCO.20.01820
Wu YL, Tsuboi M, He J, et al (2020) Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 383(18):1711-1723. doi:10.1056/NEJMoa2027071
Felip E, Altorki N, Zhou C, et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-5
Liu SY, Bao H, Wang Q, et al (2021) Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat Commun 12(1):6450. Published 2021 Nov 8. doi:10.1038/s41467-021-26806-7
Wang Z, Cheng Y, An T, et al (2018) Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med 6(9):681-690. doi:10.1016/S2213-2600(18)30264-9
Qiu B, Guo W, Zhang F, et al (2021) Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun 12(1):6770. Published 2021 Nov 19. doi:10.1038/s41467-021-27022-z

PDF

Version 1

posted 15 Feb, 2022

You are reading this latest preprint version

Postoperative Adjuvant Treatment Options in Resected Non–Small-Cell Lung Cancer

Status:

Version 1

Abstract

Full Text

Declarations

References

Status:

Version 1